Derralynn A. Hughes
Royal Free London NHS Foundation Trust · 660 works · 17,925 citations · h-index 73
Top works
- Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study
- Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor
- Identification of macrophages and dendritic cells in the osteopetrotic (op/op) mouse
- Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease
- Macrophage recruitment during limb development and wound healing in the embryonic and foetal mouse
- Murine macrophage scavenger receptor: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non‐lymphoid organs
- Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping
- RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation.
- The Macrophage Scavenger Receptor Type A Is Expressed by Activated Macrophages and Protects the Host Against Lethal Endotoxic Shock
- Natural history of Fabry disease in females in the Fabry Outcome Survey
- Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
- Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
- Macrophage-colony-stimulating factor selectively enhances macrophage scavenger receptor expression and function.
- Upregulation of the macrophage scavenger receptor in response to different forms of injury in the CNS
- Prevalence and Clinical Significance of Cardiac Arrhythmia in Anderson-Fabry Disease
- Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
- Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
- Multiple myeloma: causes and consequences of delay in diagnosis
- Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells